[
  {
    "ts": null,
    "headline": "Medtronic Stock Rated Outperform as Renal Denervation and Spin-Off Drive Growth Potential",
    "summary": "Medtronic, Inc. (NYSE:MDT) ranks among the top stocks for an early retirement portfolio. On June 18, RBC Capital reiterated a $101 price target and an Outperform rating on Medtronic, Inc. (NYSE:MDT), emphasizing the company’s renal denervation system as an undervalued market opportunity. The firm assessed the potential of Medtronic’s Symplicity Spyral renal denervation system, which […]",
    "url": "https://finnhub.io/api/news?id=1cc534c1f4a826ad7d65f278631fc1ecf2a7af80c0489165563bc9d2d33c99ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750874976,
      "headline": "Medtronic Stock Rated Outperform as Renal Denervation and Spin-Off Drive Growth Potential",
      "id": 135528774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic, Inc. (NYSE:MDT) ranks among the top stocks for an early retirement portfolio. On June 18, RBC Capital reiterated a $101 price target and an Outperform rating on Medtronic, Inc. (NYSE:MDT), emphasizing the company’s renal denervation system as an undervalued market opportunity. The firm assessed the potential of Medtronic’s Symplicity Spyral renal denervation system, which […]",
      "url": "https://finnhub.io/api/news?id=1cc534c1f4a826ad7d65f278631fc1ecf2a7af80c0489165563bc9d2d33c99ba"
    }
  },
  {
    "ts": null,
    "headline": "Diabetes stocks rally after RFK comments on HHS campaign",
    "summary": "Sarah Karlin-Smith of Pink Sheet reported via X: “RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing “wearable” in 4 years.” Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Published first on TheFly – the ultimate source for real-time, m",
    "url": "https://finnhub.io/api/news?id=f8919b693ec3bec6111de973798f62f355c7a19d6b98367a7413ec72e326475b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750868125,
      "headline": "Diabetes stocks rally after RFK comments on HHS campaign",
      "id": 135527427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Sarah Karlin-Smith of Pink Sheet reported via X: “RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing “wearable” in 4 years.” Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Published first on TheFly – the ultimate source for real-time, m",
      "url": "https://finnhub.io/api/news?id=f8919b693ec3bec6111de973798f62f355c7a19d6b98367a7413ec72e326475b"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic recall of capsule delivery devices tied to 33 serious injuries",
    "summary": "The Food and Drug Administration published an early alert for the recall on Tuesday. No deaths have been associated with the problem.",
    "url": "https://finnhub.io/api/news?id=f011829b5f6c2e22e1aeb4ff508ea133b75d75e221abcf797993ad75aaa227d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750865640,
      "headline": "Medtronic recall of capsule delivery devices tied to 33 serious injuries",
      "id": 135528776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration published an early alert for the recall on Tuesday. No deaths have been associated with the problem.",
      "url": "https://finnhub.io/api/news?id=f011829b5f6c2e22e1aeb4ff508ea133b75d75e221abcf797993ad75aaa227d2"
    }
  },
  {
    "ts": null,
    "headline": "Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?",
    "summary": "Intuitive Surgical raises 2025 procedure outlook after strong Q1 growth, but rising costs and tariff pressure weigh on margins.",
    "url": "https://finnhub.io/api/news?id=0b9a2dc45672bc2f576e46b86b90253ae07d66bf3adbfd4468cf805185bf3781",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750853580,
      "headline": "Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?",
      "id": 135528777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Intuitive Surgical raises 2025 procedure outlook after strong Q1 growth, but rising costs and tariff pressure weigh on margins.",
      "url": "https://finnhub.io/api/news?id=0b9a2dc45672bc2f576e46b86b90253ae07d66bf3adbfd4468cf805185bf3781"
    }
  },
  {
    "ts": null,
    "headline": "United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption",
    "summary": "The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and favorable reimbursement policies. Major players: Eli Lilly, Sanofi, Glooko, Medtronic, Novo Nordisk, Owen Mumford. U.S. Insulin Pens Market U.S. Insulin Pens Market Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The \"United States Insulin Pens Market Size, Insights, Competitive Landscape, and Forecast, 2025 - 2033\"",
    "url": "https://finnhub.io/api/news?id=cbe66ed86730d81bb5f64974111a9432c236595402ab1b505b8131983ec7f73c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750845360,
      "headline": "United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption",
      "id": 135527959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and favorable reimbursement policies. Major players: Eli Lilly, Sanofi, Glooko, Medtronic, Novo Nordisk, Owen Mumford. U.S. Insulin Pens Market U.S. Insulin Pens Market Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The \"United States Insulin Pens Market Size, Insights, Competitive Landscape, and Forecast, 2025 - 2033\"",
      "url": "https://finnhub.io/api/news?id=cbe66ed86730d81bb5f64974111a9432c236595402ab1b505b8131983ec7f73c"
    }
  }
]